Sentonix, Inc.

ARLINGTON, MA · Founded 2023 · CIK 0002039609 · Biotech

Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$18M
2 Form D · Aug 2026
2 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,205,590
Private capital raisedForm D · SEC$12,704,719
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2022Enveda Therapeutics, Inc.—$67M
2023Vigil Neuroscience—$195M
2024Sedare Biosciences, Inc.—$2.5M
2025Sentonix, Inc.—$18M
2026NXT BIOLOGICS, INC.——
2027ADVANCED MOLECULAR HEALIX INC.——
2028ChemRegen Inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • John BeaverDirector · Executive Officer
  • Jack HoppinDirector
  • Karl SchmidtExecutive Officer
  • Kenan TurnaciogluDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.